Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung
cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular …

Background To compare the efficiency and toxicity of bevacizumab by intrapleural or
intravenous infusion in the management of malignant pleural effusion in patients with non …

Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer
(NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of …

Background Vascular endothelial growth factor (VEGF) plays a pivotal role in the
pathogenesis of malignant pleural effusion (MPE). Here, a multicenter phase II trial to …

Purpose The presence of malignant pleural effusion (MPE) indicates a poorer prognosis for
patients with non-small-cell lung cancer (NSCLC) and impairs their quality of life. Because …

Malignant pleural effusion (MPE) is a common complication of lung cancer with devastating
consequences. Since vascular endothelial growth factor (VEGF) has been implicated in …

Background VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …

Background Vascular endothelial growth factor (VEGF) is a critical regulator of malignant
pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and …

Aim: Malignant effusion is associated with high serum and plasma levels of vascular
endothelial growth factor (VEGF). There are no biomarkers of outcome for bevacizumab …

Malignant pleural effusion (MPE) is a severe medical condition, which can result in
breathlessness, pain, cachexia and reduced physical activity. It can occur in almost all types …